Omnipod Insulin System OK’d for T1D; Over 37M Americans With Diabetes; Bye-Bye, BPA?

The FDA cleared the Omnipod Automated Insulin Delivery System — the first tubeless device of its kind with smartphone control — for individuals as young as 6 years old with type 1 diabetes, Insulet announced.

A total of 37.3 million Americans have diabetes — representing 11.3% of the U.S. population, according to new CDC data. Of this population, 28.7 million people have been properly diagnosed while the remaining 8.5 million are undiagnosed.

In Ontario, aspirin was given to only 38.8% of pregnant women with prepregnancy diabetes, obesity, and hypertension to prevent preeclampsia. (JAMA)

Along with a slew of doctors, scientists and public health, and environmental organizations, the Endocrine Society said it added its name to a formal petition sent to the FDA to rescind approvals of bisphenol A (BPA) in adhesives and coatings and set strict limits on its use in food-facing plastics.

The Endocrine Society also announced the launch of its renewed patient outreach program, featuring new in-person health education events as well as a new consumer health education web presence.

In the second advertising blunder since December, Eli Lilly got chastised yet again by the FDA, this time for an Instagram post about Trulicity (dulaglutide) that failed to list all safety concerns. (FiercePharma)

In a study of over 1 million individuals with chronic conditions, like diabetes, those who also had psychiatric comorbidities had a significantly higher risk of all-cause death. (PLoS Medicine)

Mental health startup Cerebral had its advertisements pulled from several social media platforms, including TikTok and Instagram, after running one ad that referenced obesity is “five times more prevalent” among those with ADHD. (USA Today)

Please enable JavaScript to view the comments powered by Disqus.